SCHEMBL7067714

SCHEMBL7067714

CC(C)(C)[Si](OC[C@H]1O[C@@H](n2cnc3c(NC(=O)c4ccccc4)ncnc32)C(OCC(O)N2C(=O)c3ccccc3C2=O)C1O)(c1ccccc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 2/20 0.43
PRMT6 Q96LA8 1/20 0.43
P2RY2 P41231 1/20 0.42
P2RY1 P47900 1/20 0.42
P2RY6 Q15077 1/20 0.42
DNPH1 O43598 2/20 0.41
BMPR1B O00238 1/20 0.39
ADORA1 P30542 2/20 0.39
P2RX3 P56373 2/20 0.39
P2RX4 Q99571 2/20 0.39
P2RX2 Q9UBL9 2/20 0.39
NT5E P21589 1/20 0.38
P2RX6 O15547 1/20 0.38
P2RX1 P51575 1/20 0.38
P2RX5 Q93086 1/20 0.38
P2RY11 Q96G91 1/20 0.38
P2RX7 Q99572 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5507017 0.90 P2RY12 (0.46) P2RY12PRMT6P2RY2P2RY1P2RY6
SCHEMBL7251722 0.90 P2RY12 (0.46) P2RY12PRMT6P2RY2P2RY1P2RY6
SCHEMBL7246178 0.89 P2RY12 (0.44) P2RY12PRMT6P2RY2P2RY1P2RY6
SCHEMBL7065332 0.87 P2RY12 (0.48) P2RY12PRMT6P2RY2P2RY1P2RY6
SCHEMBL7065329 0.87 P2RY12 (0.48) P2RY12PRMT6P2RY2P2RY1P2RY6
SCHEMBL7251211 0.86 P2RY12 (0.47) P2RY12PRMT6P2RY2P2RY1P2RY6
SCHEMBL5511440 0.86 P2RY12 (0.47) P2RY12PRMT6P2RY2P2RY1P2RY6
SCHEMBL7063487 0.85 P2RY12 (0.47) P2RY12PRMT6P2RY2P2RY1P2RY6
SCHEMBL7063482 0.85 P2RY12 (0.47) P2RY12PRMT6P2RY2P2RY1P2RY6
SCHEMBL7075684 0.84 P2RY12 (0.58) P2RY12P2RY2P2RY1P2RY6DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624294-B2 Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside ISIS PHARMACEUTICALS, INC. 2003-09-23 US disclosed
US-20030078415-A1 Regioselective synthesis of 2'-O-modified nucleosides IONIS PHARMACEUTICALS, INC. 2003-04-24 US disclosed
US-6403779-B1 DISSOLVING NUCLEOSIDE IN APROTIC SOLVENT, COOLING, TREATING WITH BASE, WARMING MIXTURE, COOLING, REACTING WITH REACTIVE ESTER TO EFFECT ALKYLATION ISIS PHARMACEUTICALS, INC. 2002-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078415-A1 Regioselective synthesis of 2'-O-modified nucleosides NSUN2, NT5C3B, RNGTT P2RY12 4230/4885PRMT6 1822/4885P2RY2 3378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.